Navigation Links
Boston College biologists build a better mouse model for cancer research
Date:4/9/2008

CHESTNUT HILL, MA (4/9/08) Researchers at Boston College have developed the first laboratory mouse model that mimics cancers spread through the human body. Using their novel cell line, the team discovered one of the bodys primary defensive cells plays a role in cancers attack.

The development of a new animal model a line of cancer cells injected into a laboratory mouse that displays the full spectrum of systemic metastatic cancer in humans removes a "scientific stumbling block" in advancing cancer research and potential treatments, according to Boston College Biologist Thomas Seyfried, whose findings appear this week in the online version of the International Journal of Cancer and will be presented at the annual meeting of the American Association of Cancer Research in San Diego.

"What we have developed is the first model in the mouse that replicates all of the hallmarks of metastatic cancer," said Seyfried, the project leader. Now, we have a tool that can be effective in identifying basic mechanisms and new therapies to treat the disease.

Researchers produced two cell lines that when injected into mice express all the major biological processes of metastasis. A third line, when injected, grew rapidly, but did not lead to metastatic cancer.

Previous mouse models contain limitations in effectiveness and speed. Many models fail to produce cancer in each animal subject and it often takes several months before cancer is detected. In other models, cancer cells are transplanted into animals with disabled immune systems. Within three weeks, the two Seyfried models produced tumors in 100 percent of the mice, which had healthy immune systems.

The cell line enabled researchers to make a new discovery about metastatic cells, namely that these cells express properties of macrophages, tissue cells that usually protect organisms against invading microbes in the environment and bacteria that lead to infection and disease.

"We show that the metastatic cells have macrophage properties," said doctoral researcher Leanne Huysentruyt, the lead author of the paper, who will present the findings April 13, when the American Association for Cancer Research meets. Knowing this should allow for new types of therapies that target the macrophage-like cells.

Metastasis, the spread of cancer from a primary site to other tissues and organs within the body, is the primary cause of death among cancer patients and remains largely unmanageable. Without an animal model that consistently reproduces human-like metastases, researchers have relied primarily on individual cancer patients to assess new therapies.

"The development of new drugs for cancer lags behind basic research," said Seyfried. "How can you cure a disease when you have no model system that replicates the disease except for the sick humans? It's almost as if each person who develops the disease is a guinea pig."

Seyfried said when a person has metastatic cancer, the macrophage-like tumor cells multiply and attack the body, system by system. Human metastatic cancers include breast, lung, colon and melanoma. When injected into mice, the metastatic cancer cells spread to other systems within three weeks.

"This will have an impact on how we view the role of macrophages in cancer progression," said Huysentruyt.

Seyfrieds research was funded, in part, by a grant from the American Institute of Cancer Research, which praised the findings.

"We are happy to be able to contribute to Dr. Seyfried's academic and professional progress," said Ivana Vucenik, a spokeswoman for the institute. "As a result of our support, Dr. Seyfried has made a major advance in this field."


'/>"/>

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College
Source:Eurekalert

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology: